<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> is associated with an increased risk of oesophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>In 1985, Sontag et al reported an association between <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> and <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>This association has become controversial owing to conflicting evidence </plain></SENT>
<SENT sid="3" pm="."><plain>Two recent papers indicate that although the prevalence of colon <z:mpath ids='MPATH_270'>adenomas</z:mpath> is the same in persons with <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> as in the rest of the population, patients have an increased risk of developing <z:hpo ids='HP_0003003'>colon cancer</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>A biologically plausible hypothesis is presented which explains the predisposition to both oesophageal and <z:hpo ids='HP_0003003'>colon cancers</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>This hypothesis discusses the contribution of environmental factors such as alcohol, smoking and diet </plain></SENT>
<SENT sid="6" pm="."><plain>In addition, it is proposed that the increased expression of the cyclo-oxygenase 2 enzyme is central to the predisposition to both oesophageal and <z:hpo ids='HP_0003003'>colon cancers</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>Since this enzyme is inhibited by <z:chebi fb="2" ids="35475">non-steroidal anti-inflammatory drugs</z:chebi> such as aspirin and <z:chebi fb="0" ids="9352">sulindac</z:chebi>, these drugs hold promise as <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> chemopreventive agents in <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> patients </plain></SENT>
<SENT sid="8" pm="."><plain><z:chebi fb="0" ids="9352">Sulindac</z:chebi> is the most promising of these agents owing to its efficacy in regressing <z:mp ids='MP_0003269'>colon polyps</z:mp> in patients with <z:e sem="disease" ids="C0032580" disease_type="Neoplastic Process" abbrv="">familial adenomatous polyposis</z:e> </plain></SENT>
</text></document>